Health Canada: optimizing transparency and its impact for patients.

Citation metadata

Date: Sept. 27, 2021
From: CMAJ: Canadian Medical Association Journal(Vol. 193, Issue 38)
Publisher: CMA Joule Inc.
Document Type: Letter to the editor
Length: 555 words
Lexile Measure: 1820L

Document controls

Main content

Article Preview :

We are writing in response to the article by Egilman and colleagues published in CMAJ, "Optimizing the data available via Health Canada's clinical information portal." (1) Health Canada should be applauded for becoming a world leader in the proactive release of clinical study reports and trial protocols from submissions to support market authorization of drugs and medical devices. (1) However, these valuable documents will have an impact only to the extent that they are used. Given the well-documented biases that pervade the medical literature, (2,3) it is incumbent upon reviewers, developers of clinical practice guidelines, drug formulary decision-makers, educators and others who evaluate drugs and devices to ensure that they utilize clinical study reports and other documents now available through Health Canada.

To further improve transparency, we urge Health Canada to release its reviewer reports on product submissions,...

Source Citation

Source Citation   

Gale Document Number: GALE|A677132933